These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 5529914)

  • 21. [L-dopa and parkinsonism. A preliminary report].
    Pakkenberg H
    Ugeskr Laeger; 1969 May; 131(22):959-60. PubMed ID: 5793628
    [No Abstract]   [Full Text] [Related]  

  • 22. L-dopa in Parkinson's disease. A report on 95 cases and review of the literature.
    Lewis I
    J Med Assoc State Ala; 1971 May; 40(11):709-18. PubMed ID: 5573008
    [No Abstract]   [Full Text] [Related]  

  • 23. Intermittent levodopa therapy in parkinsonism.
    Koller WC
    Adv Neurol; 1983; 37():45-50. PubMed ID: 6407286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term treatment of Parkinson's disease with levodopa.
    Campbell JB
    Neurology; 1970 Dec; 20(12):18-22. PubMed ID: 5531291
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clinical experience with L-DOPA in the treatment of parkinsonism].
    Chiba T
    No To Shinkei; 1970 Dec; 22(12):1399-405. PubMed ID: 5536833
    [No Abstract]   [Full Text] [Related]  

  • 26. Current drug information. Levodopa. Mithramycin.
    Ann Intern Med; 1970 Sep; 73(3):445-8. PubMed ID: 5468839
    [No Abstract]   [Full Text] [Related]  

  • 27. Symposium on levodopa in Parkinson's disease. Clinical and pharmacological aspects. Where do we go from here?
    Clin Pharmacol Ther; 1971; 12(2):408-16. PubMed ID: 5577487
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 29. [Postmenopausal vaginal haemorrhage as a complication of treatment of Parkinsonism with L-dopa].
    Garde K; Kruse-Larsen C
    Ugeskr Laeger; 1971 May; 133(18):886-7. PubMed ID: 5577751
    [No Abstract]   [Full Text] [Related]  

  • 30. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
    Muhlack S; Woitalla D; Welnic J; Twiehaus S; Przuntek H; Müller T
    Neurosci Lett; 2004 Jun; 363(3):284-7. PubMed ID: 15182961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [L-DOPA therapy of parkinsonism].
    Refsum S
    Nord Med; 1969 May; 81(18):570-1. PubMed ID: 5768311
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of parkinsonism with L-dopa].
    Court J; Kase JC; Palacios E; Mena I
    Rev Med Chil; 1971 Jun; 99(6):399-401. PubMed ID: 5561157
    [No Abstract]   [Full Text] [Related]  

  • 33. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parkinson's disease: the effect of levodopa therapy on the dentition: report of case.
    Walter DC; Barbeau A
    J Am Dent Assoc; 1972 Jul; 85(1):133-8. PubMed ID: 4503584
    [No Abstract]   [Full Text] [Related]  

  • 35. [Convulsive seizures in chronic alcoholism].
    Klupp M
    Fortschr Med; 1980 Dec; 98(45):1777-9. PubMed ID: 7461573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [L-dopa effect in Parkinson's syndrome].
    Römer F; Bettag W; Bock WJ
    Z Allgemeinmed; 1971 Feb; 47(6):281-3. PubMed ID: 5571715
    [No Abstract]   [Full Text] [Related]  

  • 37. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
    Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
    Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new selective suicide inhibitor of peripheral DOPA decarboxylase.
    Wajsbort J; Youdim MB
    Adv Neurol; 1984; 40():251-8. PubMed ID: 6364729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of Parkinson's disease with L-dopa therapy.
    Tyler E
    Can Nurse; 1971 Apr; 67(4):41-2. PubMed ID: 5549360
    [No Abstract]   [Full Text] [Related]  

  • 40. Postmenopausal bleeding: another side-effect of levodopa.
    Kruse-Larsen C; Garde K
    Lancet; 1971 Apr; 1(7701):707-8. PubMed ID: 4101653
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.